false
0001408443
A8
00-0000000
QC
0001408443
2023-11-13
2023-11-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 13, 2023
MILESTONE PHARMACEUTICALS INC.
(Exact name of registrant as specified in
its charter)
Québec |
|
001-38899 |
|
Not applicable |
(state or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer Identification No.) |
1111 Dr. Frederik-Philips Boulevard, |
|
|
Suite 420 |
|
|
Montréal, Québec CA |
|
H4M 2X6 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrant's telephone number, including area code: (514) 336-0444
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section
12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which
registered |
Common Shares |
|
MIST |
|
The Nasdaq Stock Market LLC |
Indicate by check
mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§
230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).
Emerging growth
company x
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02. |
Results of Operations and Financial Condition. |
On November 13, 2023, Milestone Pharmaceuticals
Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30,
2023, which also provided a clinical and corporate update. A copy of the press release is attached as Exhibit 99.1 hereto and is
incorporated herein by reference.
Item 9.01. |
Financial Statements and Exhibits. |
(d) Exhibits.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
MILESTONE PHARMACEUTICALS INC. |
|
|
|
By: |
/s/Amit Hasija |
|
|
Amit Hasija |
|
|
Chief Financial Officer |
|
|
|
Dated: November 13, 2023 |
|
Exhibit 99.1
Milestone Pharmaceuticals
Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate Updates
| - | New Drug Application submitted to the U.S. Food and Drug Administration for CARDAMYST™, the conditionally approved
brand name for etripamil nasal spray, for patients with PSVT |
| - | Positive Phase 2 data evaluating etripamil in AFib-RVR were a Featured Science Presentation at 2023 AHA Scientific Sessions; Phase
3 program expected to begin enrollment in mid-2024 |
| - | Company to host Investor and Analyst Webcast to review data from ReVeRA Phase 2 study of etripamil in atrial fibrillation with
rapid ventricular rate today at 8:00 a.m. ET |
Montreal and Charlotte,
N.C., November 13, 2023 -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results for
the third quarter ended September 30, 2023, and provided a clinical and corporate update.
“This quarter
was transformational for our company. We believe the combination of the submission of our first New Drug Application for CARDAMYST in
treating PSVT and the release of positive results from our Phase 2 study evaluating etripamil to treat patients with AFib-RVR, demonstrates
that we are on track to advance our clinical development program,” said Joseph Oliveto, President, and Chief Executive Officer of
Milestone Pharmaceuticals. “We are approaching 2024 with a well-defined strategy and even greater confidence around the potential
of our lead asset, etripamil, to help people living with these serious heart arrythmias.”
Recent Program Updates
Etripamil for
Patients with PSVT
| · | New
Drug Application (NDA) Submitted to U.S. Food and Drug Administration (FDA) for Etripamil
in Patients with Paroxysmal Supraventricular Tachycardia (PSVT). In October, Milestone
announced the submission of an NDA to the FDA for etripamil (CARDAMYST™ conditionally
approved tradename, subject to FDA final review) in patients with PSVT. Representing the
largest data package ever studied in PSVT, the Company believes the clinical trial program
demonstrates that etripamil provided superior time to conversion to normal heart rhythm compared
to placebo. The primary analysis and supportive assessments from the pivotal RAPID Phase
3 clinical trial were recently published in The Lancet. The FDA determination
of whether the NDA is complete and accepted for review is expected by the end of 2023. If
accepted, Milestone Pharmaceuticals expects a standard review of 10 months from the the filing
of the company’s NDA. Milestone continues to advance commercial preparations to support
the anticipated launch of etripamil. |
Etripamil for Patients with AFib-RVR
| · | Positive
Results from ReVeRA Phase 2 Study of Etripamil in Atrial Fibrillation with Rapid Ventricular
Rate (AFib-RVR) Presented at the American Heart Association (AHA) Scientific Sessions 2023
and Simultaneously Published in Circulation: Arrhythmia and Electrophysiology.
In November, Milestone announced data from the ReVeRA Phase 2 study that show that
patients with AFib-RVR receiving etripamil demonstrated rapid and statistically superior
ventricular rate reduction and improved symptom-relief when compared to placebo. Safety and
tolerability reported in the 56-patient safety population who received etripamil was generally
consistent with that observed in the Company’s program for PSVT. The results were presented
as a Featured Science presentation at the American Heart Association (AHA) Scientific
Sessions 2023 and simultaneously published in Circulation: Arrhythmia and Electrophysiology.
|
| · | AFib-RVR Phase 3 Registrational Program Planned
to Begin in 2024. Based on preliminary guidance from FDA, Milestone is developing a Phase 3 registrational program to evaluate self-administered
etripamil as a potential treatment for patients with AFib-RVR. The Company expects to initiate this program in mid-2024. |
Third Quarter 2023
Financial Results
| · | As of September 30, 2023, Milestone had cash,
cash equivalents, and short-term investments of $75.7 million and 33.5 million common shares issued and outstanding, with an additional
9.6 million common shares issuable upon exercise of pre-funded warrants. Cash resources as of September 30, 2023 are expected to fund
operations into mid-2025. |
| · | Research and development expense
for the third quarter of 2023 was $6.7 million, compared with $9.8 million for the prior year period. For the nine months ended September
30, 2023, research and development expense was $25.6 million compared with $29.3 million for the prior year period. The decreases in research
and development expenses were related to lower clinical expenses and clinical personnel-related costs as a result of the completion of
phase 3 studies. |
| · | General and administrative expense
for the third quarter of 2023 was $4.2 million, compared with $4.0 million for the prior year period. For the nine months ended September
30, 2023, general and administrative expense was $12.6 million compared with $11.6 million for the prior year period. The increases were
related to personnel-related costs and consulting fees. |
| · | Commercial expense for the third
quarter of 2023 was $4.4 million, compared with $2.7 million for the prior year period. For the nine months ended September 30, 2023,
commercial expense was $10.1 million compared with $6.5 million for the prior year period. The increases were related to additional personnel
and professional costs required to expand capabilities and operations in anticipation of potential commercialization. |
| · | For the third quarter of 2023,
operating loss was $15.4 million, compared to $15.0 million for the prior year period. For the nine months ended September 30, 2023, Milestone's
operating loss was $47.3 million, compared to $45.9 million in the prior year period. |
Investor and Analyst Conference Call and Webcast
The Company will host an investor and analyst
conference call and webcast on Monday, November 13, 2023, at 8:00 a.m. Eastern Time. The event will feature a review of the ReVeRA data,
an overview of AFib-RVR and current treatment landscape, characteristics of etripamil, and commentary on next steps for Milestone's clinical
development program for etripamil. To join the live call by phone, dial (877) 870-4263 (domestic) or (412) 317-0790 (international) and
ask to be connected to the Milestone Pharmaceuticals call. To access the live or recorded webcast and accompanying slides, please visit
the News & Events section of Milestone's investor relations website at investors.milestonepharma.com.
About Paroxysmal Supraventricular Tachycardia (PSVT)
An estimated 2 million
people in the United States are currently diagnosed with PSVT which is a type of arrhythmia or abnormal heart rhythm. PSVT is characterized
by episodes of rapid heartbeats often exceeding 150 to 200 beats per minute. Key features of PSVT include the sudden occurrence of episodes
and very rapid heart rate. The heart rate can spike unpredictably and rapidly during an episode. The rapid heart rate often causes severe
palpitations, shortness of breath, chest discomfort, dizziness, or lightheadedness, and distress, forcing patients to limit their daily
activities. The uncertainty of when an episode of PSVT will strike or how long it will persist can provoke anxiety in patients and negatively
impact their day-to-day life between episodes. The impact and morbidity from an attack can be especially detrimental in patients with
underlying cardiovascular or medical conditions, such as heart failure, obstructive coronary disease, or dehydration. Many health care
providers are dissatisfied with the lack of effective treatment options in addition to a prolonged, burdensome, and costly trip to the
emergency department or, for some patients, an invasive ablation procedure.
About Atrial Fibrillation
with Rapid Ventricular Rate (AFib-RVR)
An estimated five million Americans suffer from
atrial fibrillation (AFib), a common arrhythmia marked by an irregular, disruptive and often rapid heartbeat. The incidence of AFib is
expected to grow to approximately 10 million by 2025 and up to about 12 million by 2030.1,2,3 A subset of patients with AFib
experience episodes of abnormally high heart rate most often accompanied by palpitations, shortness of breath, dizziness, and weakness.
While these episodes, known as AFib-RVR, may be treated by oral calcium channel blockers and/or beta blockers, patients frequently seek
acute care in the emergency department to address symptoms. In 2016, nearly 800,000 patients were admitted to the emergency department
due to AFib symptoms where treatment includes medically supervised intravenous administration of calcium channel blockers or beta blockers,
or electrical cardioversion. With little available data for AFib-RVR, Milestone's initial market research indicates that 30 to 40% of
patients with AFib experience one or more symptomatic episodes of RVR per year that require treatment, suggesting a target addressable
market of approximately three to four million patients in 2030 for etripamil in patients with AFib-RVR.
About Etripamil
Etripamil is Milestone's
lead investigational product. It is a novel calcium channel blocker nasal spray under clinical development for elevated and often highly
symptomatic heart-rate attacks associated with PSVT and AFib-RVR. It is designed to be a rapid-response therapy that is self-administered
by the patient, without the need for direct medical oversight. If approved, etripamil is intended to provide health care providers with
a new treatment option to enable on demand care and patient self-management. If approved, the portable, self-administered treatment may
provide patients with active management and a greater sense of control over their condition. CARDAMYST™, the conditionally
approved brand name for etripamil nasal spray, is well studied with a robust clinical trial program
that includes a completed Phase 3 clinical-stage program for the treatment of PSVT and Phase 2 proof-of-concept trial for the treatment
of patients with AFib-RVR.
About Milestone
Pharmaceuticals
Milestone Pharmaceuticals
Inc. (Nasdaq: MIST) is a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular
medicines. Milestone's lead product candidate etripamil recently completed its Phase 3 clinical-stage program for the treatment of PSVT
and a Phase 2 proof-of-concept trial for the treatment of patients with AFib-RVR. The AFib-RVR study, ReVeRA, was recently presented
as a Featured Science presentation at the American Heart Association (AHA) Scientific Sessions 2023 and simultaneously published in Circulation:
Arrhythmia and Electrophysiology. Milestone Pharmaceuticals operates in Canada and the United States. Find
out more at www.milestonepharma.com.
Forward-Looking
Statements
This press release contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believe," "continue," "could,"
"demonstrate," "designed," "develop," "estimate," "expect," "may," "pending,"
"plan," "potential," "progress," "will" and similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements
are based on Milestone's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves
risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained
in this press release include statements regarding etripamil’s potential to help patients living with these serious heart arrythmias;
etripamil’s continued ability to achieve statistically superior ventricular rate reduction and improved symptom-relief when compared
to placebo; the timing and outcome of the FDA determination of whether the NDA is complete and accepted for review; the timing of the
FDA’s potential review of the NDA; the timing of the launch of etripamil; the clinical benefit of etripamil for self-treating recurrent
episodes of PSVT without medical supervision; the timing of a Phase 3 registrational program for etripamil; and the anticipated growth
in incidences of AFib by 2025 and 2030 and the target addressable market of patients with AFib-RVR by 2030. Important factors that could
cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, the risks inherent
in biopharmaceutical product development and clinical trials, including the lengthy and uncertain regulatory approval process; uncertainties
related to the timing of initiation, enrollment, completion, evaluation and results of our clinical trials; risks and uncertainty related
to the complexity inherent in cleaning, verifying and analyzing trial data; and whether the clinical trials will validate the safety and
efficacy of etripamil for PSVT or other indications, among others, general economic, political, and market conditions, including deteriorating
market conditions due to investor concerns regarding inflation, Russian hostilities in Ukraine and ongoing disputes in Israel and Gaza
and overall fluctuations in the financial markets in the United States and abroad, risks related to pandemics and public health emergencies,
and risks related the sufficiency of Milestone's capital resources and its ability to raise additional capital in the current economic
climate. These and other risks are set forth in Milestone's filings with the U.S. Securities and Exchange Commission, including in its
annual report on Form 10-K for the year ended December 31, 2022, under the caption "Risk Factors," as such discussion may be
updated from time to time by subsequent filings Milestone may make with the U.S. Securities & Exchange Commission. Except as required
by law, Milestone assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations,
even as new information becomes available.
Milestone Pharmaceuticals Inc.
Condensed Consolidated Statements of Loss (Unaudited)
(in thousands of US dollars, except share
and per share data)
| |
Three months ended September 30, | | |
Nine months ended September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Revenue | |
$ | — | | |
$ | 1,500 | | |
$ | 1,000 | | |
$ | 1,500 | |
| |
| | | |
| | | |
| | | |
| | |
Operating expenses | |
| | | |
| | | |
| | | |
| | |
Research and development, net of tax credits | |
| 6,721 | | |
| 9,826 | | |
| 25,600 | | |
| 29,251 | |
General and administrative | |
| 4,227 | | |
| 4,034 | | |
| 12,561 | | |
| 11,595 | |
Commercial | |
| 4,412 | | |
| 2,670 | | |
| 10,137 | | |
| 6,537 | |
| |
| | | |
| | | |
| | | |
| | |
Loss from operations | |
| (15,360 | ) | |
| (15,030 | ) | |
| (47,298 | ) | |
| (45,883 | ) |
| |
| | | |
| | | |
| | | |
| | |
Interest income | |
| 1,120 | | |
| 474 | | |
| 2,921 | | |
| 672 | |
Interest expense | |
| (841 | ) | |
| — | | |
| (1,697 | ) | |
| — | |
| |
| | | |
| | | |
| | | |
| | |
Net loss and comprehensive loss | |
$ | (15,081 | ) | |
$ | (14,556 | ) | |
$ | (46,074 | ) | |
$ | (45,211 | ) |
| |
| | | |
| | | |
| | | |
| | |
Weighted average number of shares and pre-funded warrants outstanding, basic and diluted | |
| 42,973,160 | | |
| 42,491,787 | | |
| 42,920,620 | | |
| 42,339,123 | |
| |
| | | |
| | | |
| | | |
| | |
Net loss per share, basic and diluted | |
$ | (0.35 | ) | |
$ | (0.34 | ) | |
$ | (1.07 | ) | |
$ | (1.07 | ) |
Milestone Pharmaceuticals Inc.
Condensed Consolidated Balance Sheets (Unaudited)
(in thousands of US dollars, except share
data)
| |
September 30,
2023 | | |
December 31,
2022 | |
Assets | |
| | | |
| | |
| |
| | | |
| | |
Current assets | |
| | | |
| | |
Cash and cash equivalents | |
$ | 9,879 | | |
$ | 7,636 | |
Short-term investments | |
| 65,867 | | |
| 56,949 | |
Research and development tax credits receivable | |
| 569 | | |
| 331 | |
Prepaid expenses | |
| 6,961 | | |
| 6,005 | |
Other receivables | |
| 1,521 | | |
| 882 | |
Total current assets | |
| 84,797 | | |
| 71,803 | |
Operating lease assets | |
| 2,047 | | |
| 2,423 | |
Property and equipment | |
| 272 | | |
| 257 | |
Total assets | |
$ | 87,116 | | |
$ | 74,483 | |
| |
| | | |
| | |
Liabilities, and Shareholders' Equity | |
| | | |
| | |
| |
| | | |
| | |
Current liabilities | |
| | | |
| | |
Accounts payable and accrued liabilities | |
$ | 7,584 | | |
$ | 5,644 | |
Operating lease liabilities | |
| 530 | | |
| 495 | |
Total current liabilities | |
| 8,114 | | |
| 6,139 | |
Operating lease liabilities, net of current portion | |
| 1,583 | | |
| 1,996 | |
Senior secured convertible notes | |
| 48,915 | | |
| — | |
Total liabilities | |
| 58,612 | | |
| 8,135 | |
| |
| | | |
| | |
| |
| | | |
| | |
Shareholders’ Equity | |
| | | |
| | |
Common shares, no par value, unlimited shares authorized 33,481,787 shares issued and outstanding as of September 30, 2023, 34,286,002 shares issued and outstanding as of December 31, 2022 | |
| 260,502 | | |
| 273,900 | |
Pre-funded warrants - 9,577,257 issued and outstanding as of September 30, 2023 and 8,518,257 as of December 31, 2022 | |
| 48,459 | | |
| 34,352 | |
Additional paid-in capital | |
| 31,958 | | |
| 24,437 | |
Accumulated deficit | |
| (312,415 | ) | |
| (266,341 | ) |
| |
| | | |
| | |
Total shareholders’ equity | |
| 28,504 | | |
| 66,348 | |
| |
| | | |
| | |
Total liabilities and shareholders’ equity | |
$ | 87,116 | | |
$ | 74,483 | |
Contact:
Kim Fox, Vice President, Communications
kfox@milestonepharma.com
704-803-9295
v3.23.3
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionISO 3166-1 alpha-2 country code.
+ References
+ Details
Name: |
dei_EntityAddressCountry |
Namespace Prefix: |
dei_ |
Data Type: |
dei:countryCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Milestone Pharmaceuticals (NASDAQ:MIST)
Historical Stock Chart
From Apr 2024 to May 2024
Milestone Pharmaceuticals (NASDAQ:MIST)
Historical Stock Chart
From May 2023 to May 2024